WO2016117431A1 - 内耳性難聴治療薬 - Google Patents
内耳性難聴治療薬 Download PDFInfo
- Publication number
- WO2016117431A1 WO2016117431A1 PCT/JP2016/050861 JP2016050861W WO2016117431A1 WO 2016117431 A1 WO2016117431 A1 WO 2016117431A1 JP 2016050861 W JP2016050861 W JP 2016050861W WO 2016117431 A1 WO2016117431 A1 WO 2016117431A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- cells
- inner ear
- apoptosis
- alkyl
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Definitions
- the present invention relates to a therapeutic agent for inner ear deafness.
- hair cells and spiral ganglion cells in the cochlea play an important role in hearing. Since these cells have no regenerative ability, once they die, a therapeutic effect cannot be expected. For this reason, drug treatment for hearing loss is considered difficult.
- the therapeutic agents currently used for deafness include only circulatory improvement drugs and anti-inflammatory drugs for sudden deafness caused by circulatory disturbance or inflammation of the inner ear (Patent Publication No. 2004-123713). Development of drugs for hearing loss is expected.
- the present invention was made for the purpose of providing a novel apoptosis inhibitor and a therapeutic agent for inner ear hearing loss.
- One embodiment of the present invention is a drug for treating inner ear hearing loss caused by apoptosis, containing a biguanide compound represented by the following structural formula I or a rapamycin derivative represented by the following structural formula II as an active ingredient .
- the inner ear hearing loss resulting from apoptosis may be derived from Pendred syndrome.
- the biguanide compound may be metformin.
- the rapamycin derivative may be rapamycin.
- a further embodiment of the present invention is an apoptosis inhibitor containing a biguanide compound represented by the following structural formula I or a rapamycin derivative represented by the following structural formula II as an active ingredient.
- This apoptosis inhibitor may suppress apoptosis of inner ear cells.
- the biguanide compound may be metformin.
- the rapamycin derivative may be rapamycin.
- a further embodiment of the present invention is a method for examining apoptosis, comprising administering a compound represented by the following structural formula (I) or (II) to an inner ear cell in vitro, and inducing apoptosis in the inner ear cell: And a step of examining apoptosis occurring in the inner ear cell.
- a further embodiment of the present invention is a method for screening an apoptosis inhibitor, comprising administering a compound represented by the following structural formula (I) or (II) to an inner ear cell in vitro, and causing apoptosis in the inner ear cell: And the step of examining apoptosis occurring in the inner ear cells.
- a further embodiment of the present invention is a method for screening a drug for treating inner ear hearing loss caused by apoptosis, wherein a compound represented by the following structural formula (I) or (II) is applied to inner ear cells in vitro: An administration step, a step of inducing apoptosis in the inner ear cell, and a step of examining apoptosis occurring in the inner ear cell.
- a further embodiment of the present invention is a therapeutic method for treating a patient having inner ear hearing loss resulting from apoptosis, wherein the patient is provided with an effective amount of a biguanide compound represented by the following structural formula I or the following structure:
- a method of treatment comprising administering a rapamycin derivative of formula II.
- the biguanide compound or the rapamycin derivative may be administered into the tympanic chamber.
- the inner ear hearing loss resulting from apoptosis may be derived from Pendred syndrome.
- the biguanide compound may be metformin.
- the rapamycin derivative may be rapamycin.
- R 1 to R 7 are a hydrogen atom, a halogen atom, or a halogen atom, a cyano group, a C 1-6 alkyl group, a C 1-6 alkoxy group, a C 1-6 alkoxycarbonyl group, C 3, respectively.
- R 1 is C 1-6 alkyl or C 3-6 alkynyl
- R 2 is H, —CH 2 —OH or —CH 2 —CH 2 —OH
- X is ⁇ O , (H, H) or (H, OH).
- B In one Example of this invention, it is the microscope picture which showed the result of having dyed the obtained inner ear stem cell with (a) anti-PAX2 antibody, (b) anti-PAX8 antibody, (c) anti-SOX2 antibody.
- inner ear stem cells are cultured in suspension and cultured in the presence of FGF9 and FGF20 to express hair cell markers espin, myosin 7a, and prestin. It is the microscope picture which showed that.
- inner ear stem cells are cultured in suspension and cultured in the presence of FGF9 and FGF20, so that GFAP, a marker of cochlear ganglion glial cells, It is the microscope picture which showed that the calbindin and beta III tubulin which are markers express. Triple staining was performed with antibodies of GFAP, calbindin and beta III tubulin.
- it is a graph which shows that the cell viability of the inner ear cell derived from a Pendred syndrome patient iPS cell falls at the time of stress load.
- it is a graph which shows that rapamycin suppresses the fall of the cell viability shown in FIG.
- FIG. 10 is a graph showing that calpeptin cannot suppress apoptosis, which is the cause of the decrease in cell viability shown in FIG. 9, in one reference example of the present invention.
- Apoptosis inhibitor relates to apoptosis of inner ear cells containing a biguanide compound (the following structural formula I) or a rapamycin derivative (the following structural formula II) or a pharmacologically acceptable salt thereof as an active ingredient. It is an inhibitor.
- R 1 to R 7 are a hydrogen atom, a halogen atom, or a halogen atom, a cyano group, a C 1-6 alkyl group, a C 1-6 alkoxy group, a C 1-6 alkoxycarbonyl group, C 3, respectively.
- An optionally substituted substituent selected from an -8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, and a phenyl group, a C 1-6 alkyl group, a C 3-8 cycloalkyl group , A C 6-10 aryl group, a 5 or 6 membered heteroaryl group, or a 5 or 6 membered non-aromatic heterocyclic group.
- R 1 is C 1-6 alkyl or C 3-6 alkynyl
- R 2 is H, —CH 2 —OH or —CH 2 —CH 2 —OH
- X is ⁇ O , (H, H) or (H, OH).
- the inner ear cells targeted for apoptosis inhibition are not particularly limited, and inner ear cells that are susceptible to apoptosis are preferable, and those derived from animals suffering from inner ear hearing loss caused by apoptosis are more preferable.
- the inner ear deafness is not particularly limited as long as it is an inner ear deafness caused by apoptosis, and examples thereof include deafness due to Pendred syndrome and presbycusis.
- the inner ear cells that are the target of apoptosis inhibition may be cells that exist in the body of an individual organism or cultured cells.
- the species of the individual organism is not particularly limited, but vertebrates are preferred, and humans are most preferred.
- the cultured cells may be established cell lines, primary cultured cells, or inner ear cells differentiated from stem cells. Details of the method of inducing differentiation from stem cells to inner ear cells will be described later.
- the apoptosis inhibitor of the present invention can be used for inner ear cells, it is useful as a drug for treating inner ear deafness caused by apoptosis.
- the inner ear hearing loss to be treated is not particularly limited as long as it is inner ear hearing loss caused by apoptosis, and examples thereof include hearing loss due to Pendred syndrome, senile deafness, and the like.
- the treatment includes any of recovering the hearing loss, stopping the progress of the hearing loss, and preventing the hearing loss.
- Biguanide compound is a compound having the following structure (III) in which two molecules of guanidine are linked by sharing a nitrogen atom.
- the biguanide compound is a generic name for biguanides and compounds in which hydrogen of the biguanide is substituted.
- the substituent is not particularly limited, and is a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 6-10 aryl group, a 5 or 6 membered heteroaryl group, a 5 or 6 member.
- a non-aromatic heterocyclic group (C 1-6 alkyl group, C 3-8 cycloalkyl group, C 6-10 aryl group, 5- or 6-membered heteroaryl group, 5- or 6-membered non-aromatic system)
- the heterocyclic group includes a halogen atom, a cyano group, a C 1-6 alkyl group, a C 1-6 alkoxy group, a C 1-6 alkoxycarbonyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, C 2-6 alkynyl group, and optionally having a substituent selected from a phenyl group). That is, the biguanide compound includes a compound represented by the following structural formula.
- R 1 to R 7 are a hydrogen atom, a halogen atom, or a halogen atom, a cyano group, a C 1-6 alkyl group, a C 1-6 alkoxy group, a C 1-6 alkoxycarbonyl group, C 3, respectively.
- the most preferred compound is metformin having the following structural formula IV.
- Rapamycin derivative Rapamycin is a compound having the following structural formula V.
- the rapamycin derivative includes a compound represented by the following structural formula.
- rapamycin derivatives include: (1) 40-O-substituted rapamycin derivatives (eg 40-O-alkyl-rapamycin derivatives (40-O-hydroxyalkyl-rapamycin derivatives and 40-O- (2-hydroxy) -ethyl -Rapamycin)), (2) 32-deoxo-rapamycin and derivatives thereof, and 32-hydroxy-rapamycin and derivatives thereof, (3) 16-O-substituted rapamycin derivatives (eg 16-pent-2-ynyloxy-32- Deoxorapamycin, 16-pent-2-ynyloxy-32 (S or R) -dihydro-rapamycin, 16-pent-2
- stem cells are not particularly limited, and pluripotent stem cells and inner ear stem cells can be exemplified.
- the inner ear cell induction method will be described in detail using pluripotent stem cells as an example.
- This inner ear cell induction method can be performed along the following flow.
- the pluripotent stem cell is not particularly limited as long as it has differentiation pluripotency (multipotency or pluripotency), and examples thereof include embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells), Muse cells, and the like. Particularly preferred are cells having totipotency.
- the ROCK (Rho-associated ilcoiled-coil forming kinase / Rho-binding kinase) inhibitor is not particularly limited.
- Y-27632, Fasudil hydrochloride, K-115 (rehabilitation hydrochloride hydrate), DE-104 Etc. can be exemplified.
- the concentration of the ROCK inhibitor can be easily determined as appropriate, but is preferably 0.05% to 0.2%, more preferably 0.1%.
- the medium used in the first step and the second step is not particularly limited as long as it can maintain pluripotent stem cells, and mTeSR1 can be exemplified.
- the first step is preferably performed for 1 to 3 days, and more preferably for 1 to 2 days.
- the second step is preferably performed for 1 to 3 days, and more preferably for 1 to 2 days.
- the meaning in the absence of the ROCK inhibitor may be any concentration as long as the ROCK inhibitor is substantially absent, and may be contained at a level at which there is no effect.
- Examples of the serum-free medium used in the third step include DMEM / F12 + B27 + N2 + GlutaMax + Nonessential aminoacid.
- the culture in the third step is preferably performed for 2 to 6 days, more preferably 2 to 4 days, and most preferably 3 days.
- the serum-free medium used in the fourth step can be exemplified by DMEM / F12 + B27 + N2 + GlutaMax + Nonessential aminoacid, but the same serum-free medium used in the third step is preferably used.
- the growth factor at least one growth factor may be added from the group consisting of bFGF, FGF3, FGF10, and FGF19, but it is preferable to add all of them. Preferred concentrations for each are 10-50 ng / ml, 10-50 ng / ml, 10-50 ng / ml, 10-50 ng / ml. Further, it is preferable to culture in the presence of BMP4 in the first stage of culture and in the absence of BMP4 in the second stage.
- the concentration of BMP4 added in the previous period is preferably 5 to 50 ng / ml.
- the meaning of the absence of BMP4 in the later culture is that BMP4 may be substantially absent, and may be contained at a level at which there is no effect.
- the first culture is preferably performed for 2 to 6 days, more preferably 2 to 4 days, and most preferably 3 days. Further, the late culture is preferably performed for 2 to 6 days, more preferably 2 to 4 days, and most preferably 3 days.
- the inner ear stem cells thus obtained have the ability to differentiate into inner ear stem cells.
- the cell mass obtained in the fourth step is dissociated into single cells.
- the method for dissociating into single cells is not particularly limited, and for example, trypsin or actase can be used. After dissociating with an enzyme or physical treatment (such as pipetting), to remove undifferentiated cells and cell clumps, use nylon mesh etc. to select cells dissociated into single cells and remove the remaining cell clumps It is preferable to do this.
- a culture dish coated with a coating agent is used, and the cells are cultured under hypoxic conditions in order to maintain stem cell ability (sixth step).
- the coating agent to be used is not particularly limited, but poly-O-fibronectine is most preferable.
- the stem cells to be cultured may be those obtained in the fourth step or those obtained in the fifth step.
- the serum-containing medium used in this step include DMEM and F12.
- DMEM / F12 containing N2 and B27 is most preferable in addition to serum (for example, FBS).
- the oxygen concentration is preferably 4% to 10%, more preferably 4% to 6%, and most preferably 4%.
- the growth factor to be added to the culture may be at least one growth factor selected from the group consisting of bFGF, EGF, and IGF1, but all are preferably added. Preferred concentrations for each are 10-30 ng / ml, 10-30 ng / ml, 10-50 ng / ml.
- the inner ear stem cells are cultured in suspension. Specifically, first, inner ear stem cells are dissociated into single cells as in the fifth step.
- the dissociated cells are cultured in a floating state. Therefore, a dish for floating culture that can be cultured in a non-adherent state is used as the culture dish.
- a non-adhesive culture dish such as a plastic culture dish may be used.
- suspension culture means culturing the target cells or cell mass without adhering to the bottom of the incubator, and adhesion culture means adhering the target cells or cell mass to the bottom of the incubator. It means to culture.
- cells and cell clumps adhere to the bottom of the incubator means that the cells and cell clumps adhere to the bottom of the incubator through cell substrate adhesion molecules contained in ECM, A state in which cells and cell masses do not float in the culture solution even if the culture solution is shaken lightly.
- cells and cell clusters do not adhere to the bottom of the incubator, which means that the cells and cell clusters do not adhere to the bottom of the incubator through cell-substrate adhesion molecules contained in ECM, Even if it touches the bottom surface, it means a state where cells and cell masses float in the culture solution when the culture solution is shaken lightly.
- the bottom surface of the plastic dish is chemically treated or coated with an adhesive coating agent (gelatin, polylysine, agar, etc.) that promotes adhesion in order to promote cell adhesion to the substrate. It is preferable.
- the bottom surface of the plastic dish may not be treated, or may be coated with an adhesion-preventing coating agent (such as poly (2-hydroxyethyl methacrylate)) to prevent cell adhesion to the temperament. preferable.
- an adhesion-preventing coating agent such as poly (2-hydroxyethyl methacrylate)
- the medium used for the suspension culture is not particularly limited, and examples thereof include DMEM and F12.
- a medium containing external factors such as serum (for example, FBS), N2, B27, and growth factors is preferable.
- F12 is used.
- As an external factor to be added at least one growth factor may be included in the group consisting of bFGF, EGF, IGF1, Wnt3a, FGF9, FGF20, Heparin, and TGF ⁇ inhibitor, but preferably includes a growth factor and heparin. More preferably.
- Each preferable concentration is 10 to 50, 10 to 50, 10 to 100, 10 to 50, 10 to 100, 10 to 100, 1 to 50 ng / ml, but is not particularly limited.
- This suspension culture is preferably performed for 3 to 7 days, more preferably 4 to 6 days, and most preferably 5 days.
- the medium to be added is not particularly limited, and examples thereof include DMEM and F12.
- a medium containing external factors such as serum (for example, FBS), N2, B27, and growth factors is preferable, and DMEM / F12 is used as the medium.
- FBS serum
- N2, B27, and growth factors is preferable
- DMEM / F12 is used as the medium.
- an external factor to be added at least one growth factor may be included in the group consisting of bFGF, EGF, and IGF1, but it is more preferable to include all of them.
- Preferred concentrations for each are 10-30 ng / ml, 10-30 ng / ml, 10-50 ng / ml.
- the formed spheres are collected so as not to be broken, and adhesion culture is performed in the same medium.
- the medium is replaced with a new medium containing external factors such as serum (eg, FBS), N2, B27, and growth factors.
- external factors such as serum (eg, FBS), N2, B27, and growth factors.
- T3 and / or IGF1 as an external factor to be added, and it is preferable to use the same medium as that used in the first suspension culture except for the external factor.
- the preferred concentration of each is 10-100, 1-50 ng / ml.
- hair cells, support cells, cochlear ganglion cells and vascular streak cells can be differentiated.
- This culture is preferably performed for 3 days or more, more preferably 5 days or more. During this time, only the medium exchange may be performed.
- the medium used here is not particularly limited, and examples thereof include DMEM and F12.
- a medium containing serum (for example, FBS) and bFGF is preferable, and DMEM is most preferably used as the medium.
- the preferred concentration of bFGF is 1-50 ng / ml.
- This culture is preferably performed for 7 days or longer, more preferably for 10 days or longer, and most preferably for 14 days or longer. After the culture, Periotic mesenchymal cells having a fibrous cellular structure are obtained.
- cochlear fibrocytes and vascular streak cells can be obtained.
- This culture is preferably performed for 7 days or longer, more preferably for 10 days or longer, and most preferably for 14 days or longer.
- Pendrin-positive cells can be obtained by adding NaHCO 3 to a new medium from which bFGF has been removed and culturing.
- the preferred concentration of NaHCO 3 is 0.3% to 1%. This culture is preferably performed for 7 days or longer, more preferably for 10 days or longer, and most preferably for 14 days or longer.
- apoptosis inhibitor described in (1) can be used in vivo or in vitro.
- the apoptosis inhibitor When used in vivo, the apoptosis inhibitor can be formulated as follows, for example, in relation to the administration method.
- the active ingredient may further contain various commonly used ingredients as required.
- one or more pharmaceutically acceptable excipients for example, one or more pharmaceutically acceptable excipients, disintegrants, diluents, lubricants , Flavoring agents, coloring agents, sweetening agents, flavoring agents, suspending agents, wetting agents, emulsifying agents, dispersing agents, auxiliary agents, preservatives, buffering agents, binders, stabilizers, coating agents and the like.
- the administration route can be selected from systemic administration or local administration.
- an appropriate administration route is selected according to the disease, symptoms and the like.
- the drug according to the present invention can be administered by either oral route or parenteral route, but oral route is preferred.
- parenteral routes include normal intravenous administration and intraarterial administration, as well as subcutaneous, intradermal, intramuscular and intratympanic administration.
- transmucosal administration or transdermal administration can be performed.
- the dosage form is not particularly limited, and various dosage forms such as tablets, capsules, powders, granules, pills, solutions, emulsions, suspensions, solutions, spirits, for oral administration, Syrups, extracts, and elixirs can be used.
- parenteral agents include injections such as subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections; transdermal administration or patches, ointments or lotions; sublingual agents for buccal administration Oral aerosol; as well as aerosols for nasal administration; suppositories, but not limited to.
- These preparations can be produced by known methods usually used in the preparation process.
- the drug according to the present invention may be a sustained or sustained release dosage form.
- the amount of the active ingredient contained in the drug can be appropriately determined depending on the dose range of the active ingredient and the number of times of medication.
- the dose range is not particularly limited, and the effectiveness of the ingredients contained, dosage form, administration route, type of disease, subject nature (such as body weight, age, medical condition and use of other medicines), and the physician's It is appropriately selected depending on the judgment.
- an appropriate dose is, for example, about 100 mg to 3000 mg per adult day, preferably about 2250 mg or less, more preferably about 750 mg or less, about 100 mg to 2000 mg per day for children, preferably about 1500 mg or less, and more. Preferably it is about 750 mg or less.
- these dose modifications can be made using general routine experimentation for optimization well known in the art.
- the above dose can be administered once to several times a day.
- apoptosis of the inner ear cells can be suppressed.
- concentration of the apoptosis inhibitor when added to the medium is not particularly limited, but rapamycin derivatives 0.1 nM-1.0 nM and biguanide compounds 1 mM-10 mM are preferred.
- the method for treating inner ear hearing loss caused by apoptosis according to the present invention is a method for treating biguanide compounds and / or rapamycin derivatives in patients suffering from inner ear hearing loss caused by apoptosis. Administering.
- the biguanide compounds and rapamycin derivatives conform to the descriptions in (2) and (3).
- the method of administering a biguanide type compound and a rapamycin derivative is based on the method of using the apoptosis inhibitor described in (5) in vivo.
- the method for investigating apoptosis according to the present invention comprises a step of administering a biguanide compound and / or a rapamycin derivative to an inner ear cell in vitro, a step of inducing apoptosis in the inner ear cell, and an inner ear cell. Examining apoptosis.
- the biguanide compounds and rapamycin derivatives conform to the descriptions in (2) and (3).
- the biguanide compound may be a lead compound synthesized using metformin or rapamycin as a seed compound, and the rapamycin derivative may be a lead compound synthesized using rapamycin as a seed compound.
- the inner ear cells used here are as described in (1).
- a known method can be used, and examples thereof include an epoxomicin treatment (for example, treatment with 0.5 ⁇ M epoxomicin for 24 hours).
- a known method can be used as a method for examining the apoptosis occurring in the inner ear cells in this manner. For example, a method for detecting phosphatidylserine that has moved to the outside of the cell membrane due to apoptosis using Annexin V, 7-AAD (7-amino -actinomycin D) is detected to be able to penetrate the cell membrane, and SR-VAD-FMK (sulforhodamine-valyl-alanyl-aspartyl-fluoromethylketone), a caspase inhibitor, is fluorescently labeled to detect the presence of active caspase. Examples include a method for detecting, a method for detecting fragmented DNA, and the like.
- the screening method for an apoptosis inhibitor substance of the present invention comprises a step of administering a biguanide compound represented by the following structural formula, which is a candidate for an apoptosis inhibitor substance, to an inner ear cell in vitro; A step of inducing apoptosis, and a step of examining apoptosis occurring in the inner ear cells. Details of each step are in accordance with (5) and (7).
- apoptosis is similarly induced without administering the above compound to the same inner ear cells, and the resulting apoptosis is examined.
- the proportion of cells that have undergone apoptosis is compared between when the compound is administered and when the compound is not administered, and a compound that suppresses apoptosis when the compound is administered is identified as an apoptosis inhibitor.
- the drug screening method of the present invention comprises administering a biguanide compound represented by the following structural formula, which is a drug candidate, to inner ear cells in vitro.
- an apoptosis inhibitor is identified and used as a drug for treating inner ear hearing loss caused by apoptosis.
- the method for specifying an apoptosis inhibitor is according to (8).
- Pendred syndrome was cited as an example of inner ear hearing loss caused by apoptosis, but inner ear hearing loss is not limited to this disease.
- mononuclear cells were separated from patient peripheral blood specimens and expression vectors were introduced by electroporation by the following method.
- About 8 ml of blood was added to a BD vacutainer blood collection tube (with ACD solution) and mixed, and an equal amount of PBS was added and mixed.
- “Blood + PBS” was layered on top of Ficoll against the equivalent of “blood + PBS”. After centrifuging at 25 ° C. for 400 G ⁇ 30 minutes, the white turbid intermediate layer was slowly collected with a Pipetman, added with 12 ml of PBS, and centrifuged again at 25 ° C. for 200 G ⁇ 10 minutes.
- KBM-502 After removing the supernatant by aspiration, an appropriate amount of KBM-502 was added and suspended, and the number of cells was counted. 3 ⁇ 10 6 cells were dispensed into 15 ml tubes and centrifuged at 25 ° C. for 200 g ⁇ 10 minutes. After removing the supernatant, the cells are suspended in a culture medium containing a reprogramming factor expression vector, electroporated with a Nucleofector II Device, and then suspended in a blood cell medium KBM-502 containing a CD34 antibody to obtain a mouse-derived feeder. Seeded on cells.
- Reprogramming factor expression vectors are pCE-hOCT3 / 4 (0.63 ⁇ g), pCE-hSK (0.63 ⁇ g), pCE-hUL (0.63 ⁇ g), pCE-mp53DD (0.63 ⁇ g), pCXB-EBNA1 (0.50 ⁇ g). Mixed and introduced into cells.
- IPS cell colonies could be obtained 3 weeks after seeding on feeder cells, and iPS cell lines derived from each patient were established from the single colonies.
- the established iPS cell lines were confirmed for the quality of iPS cells by confirming the expression of undifferentiated markers, trigerm germ differentiation ability, and karyotype.
- fluorescent antibody staining was carried out by performing antigen activation on fixed iPS cells on a cell culture dish, followed by mouse OCT3 / 4 antibody, rabbit anti-NANOG antibody, rat anti-SSEA3 Antibody, mouse anti-SSEA4 antibody, mouse anti-TRA1-60 antibody, and mouse anti-TRA1-81 antibody were added (500 times, 1000 times, 300 times, 500 times, 500 times, 500 times, respectively).
- labeling was carried out using a fluorescent secondary antibody specific for each animal species IgG, and the expression of each embryo was confirmed by observation with a fluorescence microscope. The three embryo-like differentiation ability was confirmed by the following method.
- the iPS cells cultured on the feeder cells were separated from the feeder cells using a dissociation solution, and then suspended and cultured on a low adsorption plate (Corning Ultra-Low Attachment plate) for 1 week to form embryoid bodies.
- a dissociation solution a dissociation solution
- a low adsorption plate Corel Ultra-Low Attachment plate
- the formed embryoid body was collected and seeded in a well coated with poly-O-fibronectine.
- the seeded embryoid body was continuously cultured for 3 weeks to be differentiated. Three weeks after sowing, the three embryonic differentiation ability was confirmed by fluorescent antibody staining.
- mice immobilized on a slide are subjected to an antigen activation operation, and then mouse anti- ⁇ -3 tubulin antibody (ectodermal marker), mouse anti-SMA antibody (mesoderm marker), mouse anti-AFP Antibody (endoderm marker) was added (250 times, 150 times, 250 times, respectively). Then, it labeled using the fluorescent secondary antibody specific to each animal species IgG, and observed with the fluorescence microscope, and each expression was confirmed.
- mouse anti- ⁇ -3 tubulin antibody ectodermal marker
- mouse anti-SMA antibody mesoderm marker
- mouse anti-AFP Antibody endoderm marker
- the karyotype was determined using the G-band dyeing method, and it was confirmed that the normal karyotype was maintained in each line.
- Y27632-containing mTeSR1 was added to the well coated with Matri ⁇ ⁇ ⁇ ⁇ ⁇ Gel in 1) above.
- Day 11 Medium was replaced with fresh serum-free medium (DMEM / F12 + B27 + N2 + GlutaMax + Nonessential aminoacid + bFGF, FGF3, FGF10, FGF19)
- Day 12 Centrifuge the cells, collect the cells by centrifugation, and suspend with DMEM / F12 + N2 + B27 medium + bFGF, FGF3, FGF10, FGF19 (25 ng / ml, 25 ng / ml, 25 ng / ml, 25 ng / ml, 25 ng / ml) It became cloudy. Cells dissociated into single cells with a nylon mesh were collected and seeded in poly-O-fibronectine-coated wells.
- Culturing was performed under hypoxic conditions (O 2 4%, CO 2 5%). Thereafter, every 3 days, the medium was changed to DMEM / F12 + N2 + B27 medium + bFGF, EGF, IGF1 (20 ng / ml, 20 ng / ml, 50 ng / ml) and passaged approximately every 6 days. .
- the obtained cells were subjected to fluorescent antibody staining using anti-PAX2 antibody, anti-PAX8 antibody, and anti-SOX2 antibody, which are markers for inner ear stem cells.
- the fluorescent antibody staining the cells fixed on the slide were subjected to an antigen activation operation, and then a rabbit anti-PAX2 antibody, a mouse anti-PAX8 antibody, and a goat anti-SOX2 antibody were added (50 times, 100 times, respectively). 100-fold dilution). Then, it labeled using the fluorescent secondary antibody specific for each animal species IgG, and observed with the fluorescence microscope. As a positive control, nuclear staining was performed with Hoechst.
- DMEM / F12 + N2 + B27 medium + bFGF, EGF, IGF1, Wnt3a, FGF9, FGF20, Heparin, (+ TGF ⁇ inhibitor) concentration of each factor is 25ng / ml, 25ng / ml, 50ng / ml, 20ng / ml , 50 ng / ml, 50 ng / ml, 10 ng / ml
- suspended culture about 20000 cells / well (96 well)
- a low adsorption plate Corning Ultra-Low Attachment plate
- the spheres were collected so as not to break, transferred to a plate coated with poly-O-fibronectine and cultured for adhesion (about 5-10 spheres).
- the medium was changed to DMEM / F12 + N2 + B27 medium + T3, IGF1 (the concentration of each factor was 60 ng / ml, 10 ng / ml), and thereafter the medium was changed once every three days. Hair cells, support cells, and cochlear ganglion cells were obtained after 5 days of adhesion culture.
- the obtained cells were stained with fluorescent antibodies using Escher, Myosin 7a, and Prestin, which are markers for hair cells, using the respective antibodies (FIG. 2). Further, fluorescent antibody staining was performed on each of the antibodies for islet1, a marker for nerve cells, p27 / Kip1, a marker for hair cells, and prestin, a marker for hair cells (FIG. 3). Further, GFAP, which is a marker for cochlear ganglia, and calbindin and beta III tubulin, which are markers for mature neurons, were stained with fluorescent antibodies using the respective antibodies (FIG. 4).
- FIGS. 2 to 3 it was confirmed that hair cell markers, myosin 7a, espin, prestin-positive cells, and supporting cell markers p27kip1, ISLET1-expressing cells were induced.
- FIG. 4 cells expressing GFAP expressed by calbindin positive cells and associated glia, which are markers of cochlear neurons, were obtained at the same time.
- hair cells, supporting cells, and cochlear ganglion cells which are main cells constituting the inner ear sensory epithelial cells, are induced in a three-dimensional manner with the same arrangement as in vivo.
- antigen-stimulating operation was performed on the cells fixed on the slide, and then rabbit anti-carbonic acid dehydrogenase II antibody, anti-aquaporin 1 antibody, anti-sodium potassium ATPase Antibody and vimentin antibody, mouse anti-connexin 26, connexin 30 antibody, goat anti-pendrin antibody were added (all diluted 100 times). Then, it labeled using the fluorescent secondary antibody specific for each animal species IgG, and observed with the fluorescence microscope.
- Pendrin positive cells were induced from patient iPS cells and healthy person-derived iPS / ES cells by the method described above. The induced cells were cultured for 24 hours in the presence of Epoxomicin (0.5 ⁇ M) and loaded with cell stress.
- the inner ear cells derived from patients with Pendred syndrome are less susceptible to stress than normal cells, and the cell survival rate when a load is applied is reduced.
- Pendrin positive cells were induced from patient iPS cells and healthy person-derived iPS / ES cells by the method described above. The following operations were performed for each group on the induced cells.
- rapamycin administration group rapamycin was administered for 3 days.
- cell stress + rapamycin administration group after 2 days of rapamycin (0.2 nM) load, epoxomicin (0.5 ⁇ M) as cell stress was loaded for 24 hours simultaneously with rapamycin.
- epoxomicin 0.5 ⁇ M
- rapamycin suppresses a decrease in cell viability when a load is applied to inner ear cells derived from patients with Pendred syndrome.
- Pendrin positive cells were induced from patient iPS cells and healthy person-derived iPS / ES cells by the method described above. The following operations were performed for each group on the induced cells.
- rapamycin administration group rapamycin was administered for 3 days.
- cell stress + rapamycin administration group after administration of rapamycin (0.2 nM) for 2 days, epoxomicin (0.5 ⁇ M) was loaded as cell stress at the same time as rapamycin for 24 hours.
- epoxomicin 0.5 ⁇ M
- Pendrin positive cells were induced from patient iPS cells and healthy person-derived iPS / ES cells by the method described above. The following operations were performed for each group on the induced cells.
- rapamycin administration group rapamycin (0.2 nM) was administered for 3 days.
- cell stress + rapamycin administration group after administration of rapamycin (0.2 nM) for 2 days, epoxomicin (0.5 ⁇ M) was loaded as cell stress at the same time as rapamycin for 24 hours.
- DMSO was administered for 2 days and then only epoxomicin (0.5 ⁇ M) was loaded for 24 hours.
- metformin administration group 1 mM and 10 mM metformin were administered for 2 days, respectively, and epoxomicin (0.5 ⁇ M) was loaded as cell stress simultaneously with metformin for 24 hours.
- fluorescent antibody staining the cells fixed on the slide were subjected to an antigen activation operation, and then a goat anti-pendrin antibody and a rabbit anti-leaved caspase 3 antibody were added (100 times and 300 times, respectively).
- metformin suppresses a decrease in cell viability when a load is applied to inner ear cells derived from a Pendred syndrome patient.
- Pendrin positive cells were induced from patient iPS cells and healthy person-derived iPS / ES cells by the method described above. The following operations were performed for each group on the induced cells.
- rapamycin administration group rapamycin was administered for 3 days.
- cell stress + rapamycin administration group after administration of rapamycin (0.2 nM) for 2 days, epoxomicin (0.5 ⁇ M) was loaded as cell stress at the same time as rapamycin for 24 hours.
- DMSO was administered for 2 days and then only epoxomicin (0.5 ⁇ M) was loaded for 24 hours.
- metformin administration group 1 mM and 10 mM metformin were administered for 2 days, respectively, and epoxomicin (0.5 ⁇ M) was loaded as cell stress simultaneously with metformin for 24 hours.
- fluorescent antibody staining the cells fixed on the slide were subjected to an antigen activation operation, and then a goat anti-pendrin antibody and a rabbit anti-leaved caspase 3 antibody were added (100 times and 300 times, respectively).
- metformin suppresses apoptosis when a load is applied to inner ear cells derived from patients with Pendred syndrome.
- [result] Calpeptin is a kind of calpain inhibitor, and is known to suppress apoptosis of nerve cells in neurodegenerative diseases and the like.
- apoptosis of inner ear cells derived from iPS cells derived from Pendred syndrome patients cannot be suppressed. This indicates that it is unclear whether apoptosis of inner ear cells can be suppressed even if there is apoptosis-inhibiting activity against other cells.
- a novel apoptosis inhibitor and a therapeutic agent for inner ear hearing loss can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
(式中、R1~R7は、水素原子、ハロゲン原子、又は、それぞれハロゲン原子、シアノ基、C1-6アルキル基、C1-6アルコキシ基、C1-6アルコキシカルボニル基、C3-8シクロアルキル基、C2-6アルケニル基、C2-6アルキニル基、及びフェニル基から選ばれる置換基を有していてもよい、C1-6アルキル基、C3-8シクロアルキル基、C6-10アリール基、5若しくは6員へテロアリール基、又は5若しくは6員の非芳香族系へテロ環式基、から独立に選択される。)
(II)
(式中、R1は、C1-6アルキルまたはC3-6アルキニルであり、R2は、H、-CH2-OHまたは-CH2-CH2-OHであり、そしてXは、=O、(H,H)または(H,OH)である。)
本出願は、2015年1月19日付で出願した日本国特許出願2015-007849に基づく優先権を主張するものであり、当該基礎出願を引用することにより、本明細書に含めるものとする。
本発明は、ビグアナイド系化合物(下記構造式I)またはラパマイシン誘導体(下記構造式II)またはそれらの薬理学的に許容される塩を有効成分として含有する、内耳細胞のアポトーシス抑制剤である。
(式中、R1~R7は、水素原子、ハロゲン原子、又は、それぞれハロゲン原子、シアノ基、C1-6アルキル基、C1-6アルコキシ基、C1-6アルコキシカルボニル基、C3-8シクロアルキル基、C2-6アルケニル基、C2-6アルキニル基、及びフェニル基から選ばれる置換基を有していてもよい、C1-6アルキル基、C3-8シクロアルキル基、C6-10アリール基、5若しくは6員へテロアリール基、又は5若しくは6員の非芳香族系へテロ環式基、から独立に選択される。)
(II)
(式中、R1は、C1-6アルキルまたはC3-6アルキニルであり、R2は、H、-CH2-OHまたは-CH2-CH2-OHであり、そしてXは、=O、(H,H)または(H,OH)である。)
アポトーシス抑制の対象とする内耳細胞は特に限定されず、アポトーシスを起こしやすい内耳細胞が好ましく、アポトーシスに起因する内耳性難聴に罹患した動物由来であることがさらに好ましい。内耳性難聴は、アポトーシスに起因する内耳性難聴であれば特に限定されず、例えば、ペンドレッド症候群による難聴、老人性難聴などが例示できる。また、アポトーシス抑制の対象とする内耳細胞は、生物個体の体内に存在する細胞であっても、培養細胞であってもよい。生物個体の種は特に限定されないが、脊椎動物が好ましく、ヒトが最も好ましい。培養細胞は、樹立された細胞株であっても、初代培養細胞であっても、幹細胞から分化させた内耳細胞であってもよい。幹細胞から内耳細胞への分化誘導法の詳細は、後述する。
ビグアナイドとは、グアニジン2分子が窒素原子を共有して連なった、下記構造(III)を有する化合物である。
本明細書において、ビグアナイド系化合物は、ビグアナイドおよびビグアナイドの水素が置換された化合物の総称をいうものとする。置換基としては、特に限定されず、水素原子、ハロゲン原子、C1-6アルキル基、C3-8シクロアルキル基、C6-10アリール基、5若しくは6員へテロアリール基、5若しくは6員の非芳香族系へテロ環式基(C1-6アルキル基、C3-8シクロアルキル基、C6-10アリール基、5若しくは6員へテロアリール基、5若しくは6員の非芳香族系へテロ環式基は、ハロゲン原子、シアノ基、C1-6アルキル基、C1-6アルコキシ基、C1-6アルコキシカルボニル基、C3-8シクロアルキル基、C2-6アルケニル基、C2-6アルキニル基、及びフェニル基から選ばれる置換基を有していてもよい)などが例示できる。すなわち、ビグアナイド系化合物は、以下の構造式に示される化合物を含む。
(式中、R1~R7は、水素原子、ハロゲン原子、又は、それぞれハロゲン原子、シアノ基、C1-6アルキル基、C1-6アルコキシ基、C1-6アルコキシカルボニル基、C3-8シクロアルキル基、C2-6アルケニル基、C2-6アルキニル基、及びフェニル基から選ばれる置換基を有していてもよい、C1-6アルキル基、C3-8シクロアルキル基、C6-10アリール基、5若しくは6員へテロアリール基、又は5若しくは6員の非芳香族系へテロ環式基、から独立に選択されるが、全てが水素原子ではない。)
なお、最も好ましい化合物は、下記構造式IVを有するメトホルミンである。
(式中、R1は、C1-6アルキルまたはC3-6アルキニルであり、R2は、H、-CH2-OHまたは-CH2-CH2-OHであり、そしてXは、=O、(H,H)または(H,OH)である。)
例えば、ラパマイシン誘導体には、(1)40-O-置換ラパマイシン誘導体(例えば、40-O-アルキル-ラパマイシン誘導体(40-O-ヒドロキシアルキル-ラパマイシン誘導体や40-O-(2-ヒドロキシ)-エチル-ラパマイシンなど))、(2)32-デオキソ-ラパマイシンとその誘導体、および32-ヒドロキシ-ラパマイシンとその誘導体、(3)16-O-置換ラパマイシン誘導体(例えば16-ペント-2-イニルオキシ-32-デオキソラパマイシン、16-ペント-2-イニルオキシ-32(SまたはR)-ジヒドロ-ラパマイシン、16-ペント-2-イニルオキシ-32(SまたはR)-ジヒドロ-40-O-(2-ヒドロキシエチル)-ラパマイシン)、(4)40位の酸素基にてアシル化されるラパマイシン誘導体(例えば、40-[3-ヒドロキシ-2-(ヒドロキシ-メチル)-2-プロピオン酸メチル]-ラパマイシン(CCI779としても公知))、(5)ヘテロシクリルにより40位にて置換されるラパマイシン誘導体(例えば、40-エピ-(テトラゾリル)-ラパマイシン(ABT578としても公知))、(6)例えばWO9802441またはWO0114387に記載の、いわゆるラパログ(例えば、40-O-ホスホ-含有ラパマイシン誘導体(40-O-ジメチルホスフィニル-ラパマイシン(AP23573を含む)など))、(7)40-O-アルコキシ-アルキル-ラパマイシン誘導体(例えば、商品名バイオリムス(バイオリムスA9として開示される化合物(40-O-(2-エトキシ)-エチル-ラパマイシンを含む)、および商品名TAFA-93、AP23464、AP23675またはAP23841として開示される化合物)が含まれるが、(8)ラパマイシンが最も好ましい。
以下、幹細胞から内耳細胞への分化誘導法(以下、内耳細胞誘導法とも称する)を述べる。幹細胞は特に限定されないが、多能性幹細胞や内耳幹細胞が例示できる。以下、多能性幹細胞を例として、内耳細胞誘導法を詳述する。
多能性幹細胞から内耳幹細胞への誘導方法においては、
第1工程:多能性幹細胞をROCK阻害剤存在下で培養する工程
第2工程:ROCK阻害剤非存在下で培養する工程
第3工程:無血清培地で培養する工程
第4工程:増殖因子含有無血清培地で培養する工程
第5工程:単一細胞に解離する工程
を、この順で行う。なお、工程間には、本法には本質的ではない工程が挿入されてもかまわない。
内耳幹細胞から内耳感覚上皮、蝸牛神経節細胞及び血管条細胞への誘導方法においては、
第1工程:前記内耳幹細胞を浮遊培養する工程と、
第2工程:FGF9およびFGF20存在下で培養する工程と
をこの順で行う。なお、工程間には、本法には本質的ではない工程が挿入されてもかまわない。
内耳幹細胞からPeriotic mesenchymal 細胞への誘導方法においては、内耳幹細胞をbFGF含有培地で培養する工程を含む。なお、この方法に、本発明には本質的ではない工程が挿入されてもかまわない。
(1)に記載したアポトーシス抑制剤は、in vivoでもin vitroでも使用できる。
本発明の、アポトーシスに起因する内耳性難聴の治療方法は、アポトーシスに起因する内耳性難聴に罹患した患者に、ビグアナイド系化合物及び/またはラパマイシン誘導体を投与する工程を含む。ビグアナイド系化合物及びラパマイシン誘導体は、(2)及び(3)の記載に準じる。また、ビグアナイド系化合物やラパマイシン誘導体を投与する方法は、(5)で記載した、アポトーシス抑制剤をin vivoで使用する方法に準じる。
本発明のアポトーシスを調べる方法は、ビグアナイド系化合物及び/またはラパマイシン誘導体をin vitroで内耳細胞に投与する工程と、内耳細胞にアポトーシスを誘導する工程と、内耳細胞に生じるアポトーシスを調べる工程と、を含む。ビグアナイド系化合物及びラパマイシン誘導体は、(2)及び(3)の記載に準じる。
本発明のアポトーシス抑制物質のスクリーニング方法は、アポトーシス抑制物質の候補である下記構造式に示されるビグアナイド系化合物をin vitroで内耳細胞に投与する工程と、内耳細胞にアポトーシスを誘導する工程と、内耳細胞に生じるアポトーシスを調べる工程と、を含む。各工程の詳細は、(5)及び(7)に準じる。
本発明の薬剤のスクリーニング方法は、薬剤の候補である下記構造式に示されるビグアナイド系化合物をin vitroで内耳細胞に投与する工程と、内耳細胞にアポトーシスを誘導する工程と、内耳細胞に生じるアポトーシスを調べる工程と、を含む。各工程の詳細は、(5)及び(7)に準じる。その後、アポトーシス抑制物質を特定し、アポトーシスに起因する内耳性難聴を治療するための薬剤とする。アポトーシス抑制物質を特定する方法は、(8)に準じる。
(1-1)ペンドレッド症候群(Pendred syndrome)患者由来のiPS細胞の樹立
ペンドレッド症候群患者の末梢血から分離した単核球に対し、OCT3/41, SOX2, KLF4, LIN28, L-MYC, p53shRNA発現ベクターを導入して初期化を行った。以下、その詳細を記す。
三胚様分化能は以下の方法で確認を行った。フィーダー細胞上で培養したiPS細胞を解離液を用いてフィーダー細胞から分離後、低吸着プレート(Corning超低接着表面(Ultra-Low Attachment)プレート)上で1週間浮遊培養し胚葉体を形成した。1週間後、形成された胚葉体を回収し、poly-O-fibronectine でコートしたウエルに播種した。播種された胚葉体を3週間継続培養し、分化させた。播種後3週間で、三胚様分化能を蛍光抗体染色で確認した。蛍光抗体染色は、スライド上に固定した細胞に対して、抗原賦活化操作を行ったのち、マウス抗β-3 tubulin抗体(外胚葉マーカー)、マウス抗SMA抗体(中胚葉マーカー)、マウス抗AFP抗体(内胚葉マーカー)を加えた(それぞれ、250倍、150倍、250倍)。その後、それぞれの動物種IgGに特異的な蛍光2次抗体を使い標識し、蛍光顕微鏡で観察し各々の発現を確認した。
[分化誘導方法]
Day 0
1)1ウエル(6ウエル・プレート)をMatri Gelコーティングした。
ROCK阻害剤を含まないmTeSR1に培地交換した。
無血清培地(DMEM/F12+B27+N2+GlutaMax+Nonessential aminoacid)に培地交換した。以後、Day4まで、毎日培地交換した。
無血清培地(DMEM/F12+B27+N2+GlutaMax+Nonessential aminoacid+bFGF, FGF3, FGF10, FGF19+BMP4(25ng/ml、25 ng/ml、25 ng/ml、25ng/ml、10ng/ml))に培地交換した。以後、Day7まで、毎日培地交換した。
無血清培地(DMEM/F12+B27+N2+GlutaMax+Nonessential aminoacid +bFGF, FGF3, FGF10, FGF19(25ng/ml、25 ng/ml、25 ng/ml、25ng/ml))に培地交換した。以後DAY10まで、毎日培地交換した。
新鮮な無血清培地(DMEM/F12+B27+N2+GlutaMax+Nonessential aminoacid+bFGF,FGF3, FGF10,FGF19)に培地交換した
Day 12
細胞をアクターゼ処理後、遠心して細胞を回収し、DMEM/F12+N2+B27培地+bFGF、FGF3、FGF10、FGF19(25ng/ml、25 ng/ml、25 ng/ml、25ng/ml)で懸濁した。ナイロンメッシュで単一細胞に解離した細胞を集め、poly-O-fibronectine コートしたウエルに播種した。培養は、低酸素条件下で(O24%、CO25%)で行った。以後、3日ごとに、培地をDMEM/F12+N2+B27培地+bFGF、EGF、IGF1(20ng/ml、20 ng/ml、50 ng/ml)に交換し、約6日ごとに継代した。
得られた細胞について、内耳幹細胞のマーカーである抗PAX2抗体、抗PAX8抗体、抗SOX2抗体を用いて蛍光抗体染色を行った。蛍光抗体染色は、スライド上に固定した細胞に対して、抗原賦活化操作を行ったのち、ウサギ抗PAX2抗体、マウス抗PAX8抗体、ヤギ抗SOX2抗体を加えた(それぞれ、50倍、100倍、100倍希釈)。その後、それぞれの動物種IgGに特異的な蛍光2次抗体を使い標識し、蛍光顕微鏡で観察した。ポジティブコントロールとして、ヘキストで核染色を行った。
図1Bに示すように、約80%の細胞が、内耳幹細胞のマーカーを発現しており、この内耳幹細胞分化誘導方法が、極めて効率が高いことを示す。
[分化誘導方法]
(1-2)で作製した内耳幹細胞をアクターゼ処理して細胞をディッシュから剥離し、遠心して細胞を回収した。DMEM/F12+N2+B27培地+bFGF、EGF、IGF1、Wnt3a、FGF9、FGF20、Heparin、(+TGFβ阻害薬)(各因子の濃度は25ng/ml、25ng/ml、50ng/ml, 20ng/ml, 50ng/ml, 50ng/ml, 10ng/ml)を加え、低吸着プレート(Corning超低接着表面(Ultra-Low Attachment)プレート)上で浮遊培養した(約20000細胞/well(96well)。1日後、スフェア(細胞塊)の形成が観察され始めた。浮遊培養後5日目に培地DMEM/F12+N2+B2+bFGF、EGF、IGF1(各因子の濃度は25ng/ml、25ng/ml、50ng/ml)を等量追加した。
蛍光抗体染色は、スライド上に固定した細胞に対して、抗原賦活化操作を行ったのち、ウサギ抗ミオシンVIIa抗体、マウス抗エスピン抗体、ヤギ抗プレスチン抗体を加えた(それぞれ、200倍、100倍、50倍希釈)。その後、それぞれの動物種IgGに特異的な蛍光2次抗体を使い標識し、蛍光顕微鏡で観察した。
図2~3に示すように、有毛細胞マーカーである、ミオシン7a、エスピン、プレスチン陽性細胞、および支持細胞マーカーであるp27kip1、ISLET1発現細胞が誘導されることが確認された。また、図4に示すように、同時に蝸牛神経細胞のマーカーである、カルビンジン陽性細胞とそれに付随するグリアが発現するGFAPを発現する細胞が得られた。このように、本方法では、内耳感覚上皮細胞を構成する主要細胞である有毛細胞、支持細胞、蝸牛神経節細胞が立体上に生体内と同様の配列をもって誘導されてくる。
(1-2)で得られた内耳幹細胞をPOMC medium(DMEM500ml(D5796)、1M HEPES 5ml、FBS 30ml、bFGF(10ng/ml)2.0ml)に培地交換をして、通常酸素下で培養したところ、培養10日目位からPeriotic mesenchymal細胞が観察された。その後培養を続けると、2週間後に線維細胞状の構造となった。(図5)
線維細胞状の細胞形態になった細胞の培地をFBS(10%)+DMEM培地に培地交換し、さらに2週間程度培養すると、蝸牛線維細胞、血管条細胞が得られた。(図6)
また、FBS(10%)+DMEM培地にNaHCO3(0.375%)を添加した培地を用いることによって、ペンドリン陽性細胞が得られた。(図6)
[抗体染色]
蛍光抗体染色は、スライド上に固定した細胞に対して、抗原賦活化操作を行ったのち、ウサギ抗S100抗体およびPOU3F4抗体、マウス抗カルデスモン抗体、ヤギ抗TBX18抗体を加えた(それぞれ、3倍、100倍、100倍、50倍希釈)。その後、それぞれの動物種IgGに特異的な蛍光2次抗体を使って標識し、蛍光顕微鏡で観察した。
この方法によって誘導された内耳感覚上皮細胞に対して、80倍希釈したゲンタマイシン注射薬を10日間投与した。本薬剤の投与によりコントロール群に比較して優位に細胞数が減少しており、ゲンタマイシン投与による細胞毒性が生体と同様におこることが示された。
[抗体染色]
蛍光抗体染色は、スライド上に固定した細胞に対して、抗原賦活化操作を行ったのち、ヤギ抗ペンドリン抗体、マウス抗ユビキチン抗体、ウサギ抗LC3抗体を加えた(それぞれ、100倍、100倍、100倍希釈)。その後、それぞれの動物種IgGに特異的な蛍光2次抗体を使い標識し、蛍光顕微鏡で観察した。
図8に示すように、ペンドレッド症候群患者由来の内耳細胞では、ペンドリンが凝集体を形成し、その凝集体に、ユビキチン及びLC3bが共存する。このように、この細胞内凝集体は、ユビキチンプロテアソーム系及びオートファジーの両方で処理される。
[細胞生存率の測定]
患者iPS細胞および健常者由来iPS/ES細胞から上記方法でペンドリン陽性細胞を誘導した。誘導した細胞に対してエポキソミシン(Epoxomicin)(0.5μM)存在下で24時間培養し、細胞ストレスを負荷した。
図9に示すように、ペンドレッド症候群患者由来の内耳細胞は、正常細胞よりストレスに弱く、負荷を与えたときの細胞生存率が低下している。
[細胞生存率の測定]
患者iPS細胞および健常者由来iPS/ES細胞から上記方法でペンドリン陽性細胞を誘導した。誘導した細胞に対して、各群に対して以下のような操作を行った。ラパマイシン投与群では、3日間ラパマイシン投与を行った。細胞ストレス+ラパマイシン投与群では、ラパマイシン(0.2nM)負荷2日間後、ラパマイシンと同時に、細胞ストレスとしてエポキソミシン(0.5μM)を24時間負荷した。一方、細胞ストレス群では、DMSOを2日間投与したのちに、エポキソミシン(0.5μM)のみを24時間負荷した。
図10に示すように、ラパマイシンは、ペンドレッド症候群患者由来の内耳細胞に負荷を与えたときの細胞生存率低下を抑制する。
[Caspase 3陽性細胞の測定]
患者iPS細胞および健常者由来iPS/ES細胞から上記方法でペンドリン陽性細胞を誘導した。誘導した細胞に対して、各群に対して以下のような操作を行った。ラパマイシン投与群では、3日間ラパマイシン投与を行った。細胞ストレス+ラパマイシン投与群では、ラパマイシン(0.2nM)2日間投与後、ラパマイシンと同時に、細胞ストレスとしてエポキソミシン(0.5μM)を24時間負荷した。一方、細胞ストレス群では、DMSOを2日間投与したのちに、エポキソミシン(0.5μM)のみを24時間負荷した。
図11に示すように、ペンドレッド症候群患者由来の内耳細胞に負荷を与えたときの細胞生存率低下はアポトーシスが原因であり、ラパマイシンは、そのアポトーシスを抑制する。
[細胞生存率の測定]
患者iPS細胞および健常者由来iPS/ES細胞から上記方法でペンドリン陽性細胞を誘導した。誘導した細胞に対して、各群に対して以下のような操作を行った。ラパマイシン投与群では、3日間ラパマイシン(0.2nM)投与を行った。細胞ストレス+ラパマイシン投与群では、ラパマイシン(0.2nM)2日間投与後、ラパマイシンと同時に、細胞ストレスとしてエポキソミシン(0.5μM)を24時間負荷した。細胞ストレス群では、DMSOを2日間投与したのちに、エポキソミシン(0.5μM)のみを24時間負荷した。メトホルミン投与群ではそれぞれ1mM、10mMのメトホルミンを2日間投与後、メトホルミンと同時に細胞ストレスとしてエポキソミシン(0.5μM)を24時間負荷した。蛍光抗体染色は、スライド上に固定した細胞に対して、抗原賦活化操作を行ったのち、ヤギ抗ペンドリン抗体、ウサギ抗Cleaved Caspase 3抗体を加えた(それぞれ、100倍、300倍)。その後、核染色をHoechst33258(1000倍希釈)で行い、それぞれの動物種IgGに特異的な蛍光2次抗体を使い標識し、蛍光顕微鏡で観察し、視野内のペンドリン陽性かつCleaved caspase 3陰性細胞数をカウントした。
図12に示すように、メトホルミンは、ペンドレッド症候群患者由来の内耳細胞に負荷を与えたときの細胞生存率低下を抑制する。
[細胞生存率の測定]
患者iPS細胞および健常者由来iPS/ES細胞から上記方法でペンドリン陽性細胞を誘導した。誘導した細胞に対して、各群に対して以下のような操作を行った。ラパマイシン投与群では、3日間ラパマイシン投与を行った。細胞ストレス+ラパマイシン投与群では、ラパマイシン(0.2nM)2日間投与後、ラパマイシンと同時に、細胞ストレスとしてエポキソミシン(0.5μM)を24時間負荷した。細胞ストレス群では、DMSOを2日間投与したのちに、エポキソミシン(0.5μM)のみを24時間負荷した。メトホルミン投与群ではそれぞれ1mM、10mMのメトホルミンを2日間投与後、メトホルミンと同時に細胞ストレスとしてエポキソミシン(0.5μM)を24時間負荷した。蛍光抗体染色は、スライド上に固定した細胞に対して、抗原賦活化操作を行ったのち、ヤギ抗ペンドリン抗体、ウサギ抗Cleaved Caspase 3抗体を加えた(それぞれ、100倍、300倍)。その後、核染色をHoechst33258(1000倍希釈)で行い、それぞれの動物種IgGに特異的な蛍光2次抗体を使い標識し、蛍光顕微鏡で観察し、視野内のペンドリン陽性かつCleaved caspase 3陽性細胞数をカウントした。
図13に示すように、メトホルミンは、ペンドレッド症候群患者由来の内耳細胞に負荷を与えたときのアポトーシスを抑制する。
(VI)
[細胞生存率の測定]
患者iPS細胞および健常者由来iPS/ES細胞から上記方法でペンドリン陽性細胞を誘導した。誘導した細胞に対して、各群に対して以下のような操作を行った。カルペプチン投与群では、3日間カルペプチン投与を行った。細胞ストレス+カルペプチン投与群では、カルペプチン(50μM)2日間投与後、カルペプチンと同時に、細胞ストレスとしてエポキソミシン(0.5μM)を24時間負荷した。一方、細胞ストレス群では、DMSOを2日間投与したのちに、エポキソミシン(0.5μM)のみを24時間負荷した。
カルペプチンは、カルパイン阻害剤の一種であり、神経変性疾患などにおける神経細胞のアポトーシスを抑制することが知られている。しかしながら、図14に示すように、ペンドレッド症候群患者iPS細胞由来の内耳細胞のアポトーシスを抑制することができない。このことは、他の細胞に対してアポトーシス抑制活性があったとしても、内耳細胞のアポトーシスを抑制することができるかどうかは不明であることを示す。
Claims (11)
- 下記構造式Iに示されるビグアナイド系化合物または下記構造式IIに示されるラパマイシン誘導体を有効成分として含有する、アポトーシスに起因する内耳性難聴を治療するための薬剤。
(I)
(式中、R1~R7は、水素原子、ハロゲン原子、又は、それぞれハロゲン原子、シアノ基、C1-6アルキル基、C1-6アルコキシ基、C1-6アルコキシカルボニル基、C3-8シクロアルキル基、C2-6アルケニル基、C2-6アルキニル基、及びフェニル基から選ばれる置換基を有していてもよい、C1-6アルキル基、C3-8シクロアルキル基、C6-10アリール基、5若しくは6員へテロアリール基、又は5若しくは6員の非芳香族系へテロ環式基、から独立に選択される。)
(II)
(式中、R1は、C1-6アルキルまたはC3-6アルキニルであり、R2は、H、-CH2-OHまたは-CH2-CH2-OHであり、そしてXは、=O、(H,H)または(H,OH)である。) - 前記アポトーシスに起因する内耳性難聴が、ペンドレッド症候群に由来する、請求項1に記載の薬剤。
- 前記ビグアナイド系化合物がメトホルミンである、請求項1または2に記載の薬剤。
- 前記ラパマイシン誘導体がラパマイシンである、請求項1または2に記載の薬剤。
- 下記構造式Iに示されるビグアナイド系化合物または下記構造式IIに示されるラパマイシン誘導体を有効成分として含有する、アポトーシス抑制剤。
(I)
(式中、R1~R7は、水素原子、ハロゲン原子、又は、それぞれハロゲン原子、シアノ基、C1-6アルキル基、C1-6アルコキシ基、C1-6アルコキシカルボニル基、C3-8シクロアルキル基、C2-6アルケニル基、C2-6アルキニル基、及びフェニル基から選ばれる置換基を有していてもよい、C1-6アルキル基、C3-8シクロアルキル基、C6-10アリール基、5若しくは6員へテロアリール基、又は5若しくは6員の非芳香族系へテロ環式基、から独立に選択される。)
(II)
(式中、R1は、C1-6アルキルまたはC3-6アルキニルであり、R2は、H、-CH2-OHまたは-CH2-CH2-OHであり、そしてXは、=O、(H,H)または(H,OH)である。) - 内耳細胞のアポトーシスを抑制する、請求項5に記載のアポトーシス抑制剤。
- 前記ビグアナイド系化合物がメトホルミンである、請求項5または6に記載のアポトーシス抑制剤。
- 前記ラパマイシン誘導体がラパマイシンである、請求項5または6に記載のアポトーシス抑制剤。
- アポトーシスを調べる方法であって、
下記構造式(I)または(II)に示される化合物をin vitroで内耳細胞に投与する工程と、
前記内耳細胞にアポトーシスを誘導する工程と、
前記内耳細胞に生じるアポトーシスを調べる工程と、
を含む方法。
(I)
(式中、R1~R7は、水素原子、ハロゲン原子、又は、それぞれハロゲン原子、シアノ基、C1-6アルキル基、C1-6アルコキシ基、C1-6アルコキシカルボニル基、C3-8シクロアルキル基、C2-6アルケニル基、C2-6アルキニル基、及びフェニル基から選ばれる置換基を有していてもよい、C1-6アルキル基、C3-8シクロアルキル基、C6-10アリール基、5若しくは6員へテロアリール基、又は5若しくは6員の非芳香族系へテロ環式基、から独立に選択される。)
(II)
(式中、R1は、C1-6アルキルまたはC3-6アルキニルであり、R2は、H、-CH2-OHまたは-CH2-CH2-OHであり、そしてXは、=O、(H,H)または(H,OH)である。) - アポトーシス抑制物質のスクリーニング方法であって、
下記構造式(I)または(II)に示される化合物をin vitroで内耳細胞に投与する工程と、
前記内耳細胞にアポトーシスを誘導する工程と、
前記内耳細胞に生じるアポトーシスを調べる工程と、
を含む方法。
(I)
(式中、R1~R7は、水素原子、ハロゲン原子、又は、それぞれハロゲン原子、シアノ基、C1-6アルキル基、C1-6アルコキシ基、C1-6アルコキシカルボニル基、C3-8シクロアルキル基、C2-6アルケニル基、C2-6アルキニル基、及びフェニル基から選ばれる置換基を有していてもよい、C1-6アルキル基、C3-8シクロアルキル基、C6-10アリール基、5若しくは6員へテロアリール基、又は5若しくは6員の非芳香族系へテロ環式基、から独立に選択される。)
(II)
(式中、R1は、C1-6アルキルまたはC3-6アルキニルであり、R2は、H、-CH2-OHまたは-CH2-CH2-OHであり、そしてXは、=O、(H,H)または(H,OH)である。)
- アポトーシスに起因する内耳性難聴を治療するための薬剤のスクリーニング方法であって、
下記構造式(I)または(II)に示される化合物をin vitroで内耳細胞に投与する工程と、
前記内耳細胞にアポトーシスを誘導する工程と、
前記内耳細胞に生じるアポトーシスを調べる工程と、
を含む方法。
(I)
(式中、R1~R7は、水素原子、ハロゲン原子、又は、それぞれハロゲン原子、シアノ基、C1-6アルキル基、C1-6アルコキシ基、C1-6アルコキシカルボニル基、C3-8シクロアルキル基、C2-6アルケニル基、C2-6アルキニル基、及びフェニル基から選ばれる置換基を有していてもよい、C1-6アルキル基、C3-8シクロアルキル基、C6-10アリール基、5若しくは6員へテロアリール基、又は5若しくは6員の非芳香族系へテロ環式基、から独立に選択される。)
(II)
(式中、R1は、C1-6アルキルまたはC3-6アルキニルであり、R2は、H、-CH2-OHまたは-CH2-CH2-OHであり、そしてXは、=O、(H,H)または(H,OH)である。)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16740038.1A EP3248597B1 (en) | 2015-01-19 | 2016-01-13 | Therapeutic agent for sensorineural hearing loss |
FIEP16740038.1T FI3248597T3 (fi) | 2015-01-19 | 2016-01-13 | Terapeuttinen aine sensorineuraaliseen kuulonmenetykseen |
DK16740038.1T DK3248597T3 (da) | 2015-01-19 | 2016-01-13 | Terapeutisk middel til sensorineuralt høretab |
JP2016570589A JP6716139B2 (ja) | 2015-01-19 | 2016-01-13 | 内耳性難聴治療薬 |
US15/544,419 US11058669B2 (en) | 2015-01-19 | 2016-01-13 | Therapeutic agents for inner ear hearing impairment |
EP17187312.8A EP3295939B1 (en) | 2015-01-19 | 2016-01-13 | Therapeutic agent for treating sensorineural hearing loss |
US15/654,267 US11013725B2 (en) | 2015-01-19 | 2017-07-19 | Therapeutic agents for inner ear hearing impairment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-007849 | 2015-01-19 | ||
JP2015007849 | 2015-01-19 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/544,419 A-371-Of-International US11058669B2 (en) | 2015-01-19 | 2016-01-13 | Therapeutic agents for inner ear hearing impairment |
US15/654,267 Continuation US11013725B2 (en) | 2015-01-19 | 2017-07-19 | Therapeutic agents for inner ear hearing impairment |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016117431A1 true WO2016117431A1 (ja) | 2016-07-28 |
Family
ID=56416978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/050861 WO2016117431A1 (ja) | 2015-01-19 | 2016-01-13 | 内耳性難聴治療薬 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11058669B2 (ja) |
EP (2) | EP3295939B1 (ja) |
JP (2) | JP6716139B2 (ja) |
DK (1) | DK3248597T3 (ja) |
ES (1) | ES2928593T3 (ja) |
FI (1) | FI3248597T3 (ja) |
PT (1) | PT3248597T (ja) |
WO (1) | WO2016117431A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020521467A (ja) * | 2017-05-26 | 2020-07-27 | カイト ファーマ インコーポレイテッドKite Pharma, Inc | 胚性間葉系始原細胞の製造方法及び使用方法 |
US11147248B2 (en) | 2017-09-21 | 2021-10-19 | Keio University | Method for producing acoustic trauma deafness model animal, and acoustic trauma deafness model animal produced by the same |
WO2021251419A1 (ja) * | 2020-06-09 | 2021-12-16 | 株式会社オトリンク | 内耳有毛細胞の製造方法、薬剤の評価方法、及び細胞分化誘導用組成物 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101785455B1 (ko) * | 2016-03-16 | 2017-11-20 | 전남대학교산학협력단 | 귀리 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 약제학적 조성물 |
CN108310386A (zh) * | 2018-04-09 | 2018-07-24 | 南方医科大学 | mTOR信号通路抑制剂在制备预防或治疗非遗传性听力障碍药物中的用途 |
KR20220146349A (ko) * | 2021-04-23 | 2022-11-01 | 연세대학교 산학협력단 | 오토파지 활성화제를 유효성분으로 포함하는 비증후군성 상염색제-우성 난청의 예방 또는 치료용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003519655A (ja) * | 2000-01-14 | 2003-06-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | リンパ増殖症候群の緩和および阻害のためのo−メチル化ラパマイシン誘導体 |
JP2004099537A (ja) * | 2002-09-10 | 2004-04-02 | Sanwa Kagaku Kenkyusho Co Ltd | 難聴疾患の予防又は治療剤 |
JP2004123713A (ja) * | 2002-08-05 | 2004-04-22 | Mitsubishi Pharma Corp | 突発性難聴の予防及び/又は治療のための医薬 |
JP2010527361A (ja) * | 2007-05-17 | 2010-08-12 | キネックス ファーマシューティカルズ, エルエルシー | キナーゼカスケードを調節するための組成物の調製のための方法ならびにその使用方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3963495B2 (ja) | 1995-05-22 | 2007-08-22 | 生化学工業株式会社 | アポトーシス惹起抑制剤 |
EP0937082A2 (en) | 1996-07-12 | 1999-08-25 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
ES2219388T3 (es) | 1999-08-24 | 2004-12-01 | Ariad Gene Therapeutics, Inc. | 28-epi-rapalogos. |
US7387614B2 (en) | 2003-08-26 | 2008-06-17 | University Of Maryland, Baltimore | Drug delivery to the inner ear and methods of using same |
NZ563003A (en) | 2005-04-27 | 2011-03-31 | Univ Florida | Use of a farnesyl transferase inhibitor to enhance autophagic protein degradation in protein conformation disorders |
WO2008022256A2 (en) * | 2006-08-16 | 2008-02-21 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
TWI457336B (zh) | 2006-12-28 | 2014-10-21 | Kinex Pharmaceuticals Llc | 調節激酶級聯之組成物及方法 |
KR101390607B1 (ko) | 2008-07-14 | 2014-05-19 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 귀 질환 치료를 위한 제어 방출형 아폽토시스 조절 조성물 및 방법 |
CN102612564B (zh) | 2009-04-10 | 2015-08-26 | 齐海燕 | 新的抗衰老试剂及其鉴别方法 |
-
2016
- 2016-01-13 EP EP17187312.8A patent/EP3295939B1/en active Active
- 2016-01-13 ES ES17187312T patent/ES2928593T3/es active Active
- 2016-01-13 DK DK16740038.1T patent/DK3248597T3/da active
- 2016-01-13 WO PCT/JP2016/050861 patent/WO2016117431A1/ja active Application Filing
- 2016-01-13 JP JP2016570589A patent/JP6716139B2/ja active Active
- 2016-01-13 US US15/544,419 patent/US11058669B2/en active Active
- 2016-01-13 PT PT167400381T patent/PT3248597T/pt unknown
- 2016-01-13 FI FIEP16740038.1T patent/FI3248597T3/fi active
- 2016-01-13 EP EP16740038.1A patent/EP3248597B1/en active Active
-
2017
- 2017-05-24 JP JP2017102712A patent/JP6708346B2/ja active Active
- 2017-07-19 US US15/654,267 patent/US11013725B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003519655A (ja) * | 2000-01-14 | 2003-06-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | リンパ増殖症候群の緩和および阻害のためのo−メチル化ラパマイシン誘導体 |
JP2004123713A (ja) * | 2002-08-05 | 2004-04-22 | Mitsubishi Pharma Corp | 突発性難聴の予防及び/又は治療のための医薬 |
JP2004099537A (ja) * | 2002-09-10 | 2004-04-02 | Sanwa Kagaku Kenkyusho Co Ltd | 難聴疾患の予防又は治療剤 |
JP2010527361A (ja) * | 2007-05-17 | 2010-08-12 | キネックス ファーマシューティカルズ, エルエルシー | キナーゼカスケードを調節するための組成物の調製のための方法ならびにその使用方法 |
Non-Patent Citations (11)
Title |
---|
FANG, BIN ET AL.: "Rapamycin alleviates cisplatin-induced ototoxicity in vivo", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 448, no. 4, 2014, pages 443 - 447, XP055438585 * |
GLUTZ, ANDREA ET AL.: "Metformin Protects Auditory Hair Cells from Gentamicin-Induced Toxicity in vitro", AUDIOLOGY & NEUROTOLOGY, vol. 20, no. 6, September 2015 (2015-09-01), pages 360 - 369, XP009502616 * |
HARRIS, KELLY CARNEY ET AL.: "Prevention of noise-induced hearing loss with Src-PTK inhibitors", HEARING RESEARCH, vol. 208, no. 1-2, 2005, pages 14 - 25, XP005105480 * |
HAYASHI, KEN ET AL.: "Molecular crosstalk between Nrf2/ Keapl signaling pathway, autophagy and necrosis in auditory cells", OTOLARYNGOLOGY - HEAD AND NECK SURGERY, vol. 145, no. 2, August 2011 (2011-08-01), pages 221, XP055438587 * |
JUNG, HAK HYUN ET AL.: "Protective role of antidiabetic drug metformin against gentamicin induced apoptosis in auditory cell line", HEARING RESEARCH, vol. 282, no. 1-2, 2011, pages 92 - 96, XP028126678 * |
LECLERC, GILLES M. ET AL.: "Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts", PLOS ONE, vol. 8, no. 8, 2013, pages e74420, XP055438583 * |
LEITMEYER, KATHARINA ET AL.: "Inhibition of mTOR by rapamycin results in auditory hair cell damage and decreased spiral ganglion neuron outgrowth and neurite formation In Vitro", BIOMED RESEARCH INTERNATIONAL, vol. 21, no. 2, 31 March 2015 (2015-03-31), pages 1 - 11, XP055438590 * |
OISHI, NAOKI ET AL.: "Metformin protects against gentamicin-induced hair cell death in vitro but not ototoxicity in vivo", NEUROSCIENCE LETTERS, vol. 583, 2014, pages 65 - 69, XP029088678 * |
ROSA, CONDE DE LA ET AL.: "Oxidative stress induced apoptosis is inhibited by metformin via an ERK and Src dependent pathway in rat hepatocytes", EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol. 18, no. 1, 2006, pages A50 - A51, XP009502617 * |
See also references of EP3248597A4 * |
WOLTMAN, ANDREA M. ET AL.: "Rapamycin induces apoptosis in monocyte- and CD 34-derived dendritic cells but not in monocytes and macrophages", BLOOD, vol. 98, no. 1, 2001, pages 174 - 180, XP055438588 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020521467A (ja) * | 2017-05-26 | 2020-07-27 | カイト ファーマ インコーポレイテッドKite Pharma, Inc | 胚性間葉系始原細胞の製造方法及び使用方法 |
JP7014820B2 (ja) | 2017-05-26 | 2022-02-01 | カイト ファーマ インコーポレイテッド | 胚性間葉系始原細胞の製造方法及び使用方法 |
JP2022058672A (ja) * | 2017-05-26 | 2022-04-12 | カイト ファーマ インコーポレイテッド | 胚性間葉系始原細胞の製造方法及び使用方法 |
US11147248B2 (en) | 2017-09-21 | 2021-10-19 | Keio University | Method for producing acoustic trauma deafness model animal, and acoustic trauma deafness model animal produced by the same |
WO2021251419A1 (ja) * | 2020-06-09 | 2021-12-16 | 株式会社オトリンク | 内耳有毛細胞の製造方法、薬剤の評価方法、及び細胞分化誘導用組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP3248597A1 (en) | 2017-11-29 |
US11013725B2 (en) | 2021-05-25 |
US20170333403A1 (en) | 2017-11-23 |
EP3248597B1 (en) | 2024-03-13 |
EP3248597A4 (en) | 2018-10-10 |
US11058669B2 (en) | 2021-07-13 |
DK3248597T3 (da) | 2024-04-08 |
ES2928593T3 (es) | 2022-11-21 |
JPWO2016117431A1 (ja) | 2017-11-02 |
FI3248597T3 (fi) | 2024-04-17 |
JP6708346B2 (ja) | 2020-06-10 |
US20170340586A1 (en) | 2017-11-30 |
JP2017200923A (ja) | 2017-11-09 |
EP3295939A1 (en) | 2018-03-21 |
EP3295939B1 (en) | 2022-09-21 |
PT3248597T (pt) | 2024-03-25 |
JP6716139B2 (ja) | 2020-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6708346B2 (ja) | 内耳性難聴治療薬 | |
KR102487142B1 (ko) | 만능 세포를 분화시키는 방법 | |
JP7029144B2 (ja) | 腺性下垂体又はその前駆組織の製造方法 | |
CN104321062B (zh) | 干细胞微粒 | |
JP2020146060A (ja) | 中脳ドーパミン(mDA)ニューロンのin vitro分化の方法 | |
US9347041B2 (en) | Method for preparing corneal endothelial cell | |
Okumura et al. | Cell surface markers of functional phenotypic corneal endothelial cells | |
AU2016216570B2 (en) | Differentiated pluripotent stem cell progeny depleted of extraneous phenotypes | |
CN111269885A (zh) | 制备端脑或其前体组织的方法 | |
JP6468843B2 (ja) | ヒト網膜前駆細胞の表現型プロファイル | |
JP2022088676A (ja) | 幹細胞由来外胚葉系統前駆体を分化する方法 | |
WO2021201175A1 (ja) | 下垂体ホルモン産生細胞及びその前駆細胞の分離法 | |
KR20200046099A (ko) | 줄기 세포-유도 외배엽 계통 전구체의 분화 방법 | |
JP6954531B2 (ja) | 高機能分化誘導細胞の濃縮方法及び高機能分化誘導細胞集団 | |
Konovalova et al. | Phenotypical differences in neuronal cultures derived via reprogramming the fibroblasts from patients carrying mutations in parkinsonian genes LRRK2 and PARK2 | |
JP6615616B2 (ja) | アダルト型オリゴデンドロサイト前駆細胞の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16740038 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016570589 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15544419 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2016740038 Country of ref document: EP |